Notice of Results

RNS Number : 2431E

Diaceutics PLC

27 February 2020

 

Diaceutics PLC

("Diaceutics" or the "Company")

Notice of results

Analyst & investor briefing

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces it will release its preliminary results for the year ended 31 December 2019 on Monday 16 March 2020.

Analyst briefing

The Company will host a briefing for analysts which will take place at 9.30am on Monday 16 March 2020 in the City of London. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [e-mail].  

Investor Briefing

The Company will host a private investor event which will take place on Monday 16 March at the Copper Bar, Balls Brothers, 6 Adams Court, London EC2N 1DX at 4.30pm for a 4.45pm start. This will be followed by drinks and canapés, and a chance to network with the management.

Peter Keeling, CEO, will update investors on the Company's preliminary results and provide an overview of the business.

If you would like to register to attend the investor briefing or require further information, please contact Walbrook PR on 020 7933 8780 or email   [e-mail] .

Enquiries:

Diaceutics PLC	www.diaceutics.com
Peter Keeling, Chief Executive Officer	via Walbrook PR
Philip White, Chief Financial Officer
Cenkos Securities plc (Nominated adviser and broker)			[phone]
Callum Davidson / Giles Balleny
Michael Johnson (Sales)
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]
Paul McManus		Mob: [phone]

About Diaceutics

Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies.  The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing.  By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes.  The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

 

END

 

 

NORUNUVRRVUUUAR